NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
Clinical Trials
17 trialsNCT01970358 2025-12-29
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
Phase 1 Completed
NCT05111353 2025-11-05
Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Washington University School of Medicine
Phase 1 Completed
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT03359239 2023-05-16
Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT00616941 2022-10-12
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT03262103 2022-09-10
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT01834248 2022-07-22
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT02544880 2021-06-15
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC
University of Miami
Phase 1 Completed
NCT03380871 2021-02-26
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
BioNTech SE
Phase 1 Completed
NCT02897765 2021-02-25
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
BioNTech SE
Phase 1 Completed
NCT02721043 2021-01-11
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02947854 2019-08-28
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
PCI Biotech AS
Phase 1 Completed
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT01241162 2017-05-09
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
Phase 1 Completed
NCT01410968 2016-12-09
A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma
Medical University of South Carolina
Phase 1 Completed
NCT01008527 2015-09-24
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed